Introduction to Autoimmune Disease Drugs
Autoimmune disease is a condition in which the immune system is unable to recognize the body’s own cells and starts attacking them. The immune system might attack different types of body cells, depending on which the autoimmune disease is classified. This disease might result in degradation as well as improper functioning of body organs.
Autoimmune disease can be either localized or systemic. The immune system acts on a particular part of the body in case of localized autoimmune disease, such as thyroiditis and juvenile diabetes. On the other hand, in case of a systemic autoimmune disease, the immune system targets cells of the entire body which can be observed, for instance, in disease such as rheumatoid arthritis and lupus. Autoimmune disease is chronic in nature and there is no permanent cure available. However, the immune system action can be prevented to some extent in order to substantially reduce and inhibit its functioning.
Market Size and Forecast
The autoimmune disease drugs market is anticipated to record a CAGR of around 5% over the forecast period, i.e., 2020-2028. The market is segmented by drug, by disease, by distribution channel and by region. Based on disease, the market is segmented into rheumatoid arthritis, type 1 diabetes, multiple sclerosis, psoriasis, lupus, inflammatory bowel disease and others. The high prevalence of rheumatoid arthritis globally can be attributed to the significantly high share of this segment in the market over the next few years. On the basis of drugs, the market is segmented into NSAIDs, anti-inflammatory, interferons, antihyperglycemics and others, out of which, the anti-inflammatory segment is anticipated to hold the largest share in the autoimmune disease drugs market on account of their application in large number of indications such as rheumatoid arthritis, juvenile idiopathic arthritis, gout, psoriasis, ankylosing spondylitis and others. XELJANZ, a drug for oral use manufactured by Pfizer and approved by the U.S. FDA in 2012, aimed at treating both rheumatoid arthritis and psoriatic arthritis among adult patients having an inadequate response to methotrexate. CLICK TO DOWNLOAD SAMPLE REPORT
Improvement In Government Regulations Regarding Drug Approvals To Drive Autoimmune Disease Drugs Market
Recently, a few autoimmune disease drugs have received approvals for sale in the market. For instance, RITUXIN is a drug manufactured by Genentech, which received FDA approval for the treatment of rheumatoid arthritis. Various other drugs are still in the clinical trials stage and observing positive results. This is anticipated to become a major factor for the growth of autoimmune disease drugs market over the forecast period. The increasing research and development in the area of autoimmune disease is predicted to lead to more drug approvals in future.
Rising Awareness about Autoimmune Disease to Boost the Market Growth
Growing prevalence of various autoimmune diseases poses a high risk to individuals, especially the elderly population. Rheumatoid arthritis is an autoimmune disease in which the immune system attacks the joints in the body, commonly those in hands, knees and wrists. This causes inflammation in the affected body part and inhibits normal body functioning. According to Centers for Disease Prevention and Control, around 22.7% or 54.4 million adults in America had doctor-diagnosed arthritis as per the National Health Interview Survey 2013-3015, with a higher prevalence in women (23.5%) than in men (18.1%). The growing demand for reducing the effects of this disorder is anticipated to result in growth of the market.
High Cost Of Treatment To Restrict The Market Growth
The high cost of treatment for autoimmune disease coupled with availability of alternate treatment methods in the market are some major factors estimated to hinder the growth of autoimmune disease market over the forecast period.
Our in-depth analysis of the autoimmune disease drugs market includes the following segments:
By Distribution Channel
On the basis of regional analysis, the autoimmune disease drugs market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market is predicted to observe lucrative growth opportunities in North America as a result of rising research and development activities focused on finding a treatment for autoimmune disease. Moreover, the increasing investment in the healthcare sector in the region is another factor estimated to result in the market growth in the coming years. The highest growth rate of autoimmune disease drugs market is anticipated to be observed in the Asia Pacific region on account of significantly improving healthcare infrastructure and development of better treatment facilities. The growing awareness among people about autoimmune disease further raises the demand for the drugs in the region which is another growth driving factor for the autoimmune disease drugs market over the forecast period.
The autoimmune disease drugs market is further classified on the basis of region as follows:
Top Featured Companies Dominating the Market
Improvements in government regulations for drug approval procedures that result in higher number of drugs in the market is a major factor that is driving the growth of the market.
The market is anticipated to attain a CAGR of 5% over the forecast period, i.e. 2020-2028.
North America is anticipated to hold the dominating share in the market.
Significantly improving healthcare infrastructure and development of better treatment facilities in Asia Pacific region are anticipated to provide more business opportunities for the growth of the market in the future.
The major players in the market are Abbott Laboratories, Pfizer, AbbVie, Eli Lilly, Bristol-Myers Squibb, AstraZeneca plc, GlaxoSmithKline, F. Hoffmann-La Roche Ltd., Biogen and Amgen.
Company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.
Direct access to analyst to help you understand the market in a better way to handle your critical question
Citing your business specific requirement our consultant would assist you ensuring targeted goal is achieved
Get 10% free customization